News Archive

EUSA Pharma acquires Innocoll's Antibiotic and Pain Control Products

3 August 2007.
EUSA Pharma today announced the acquisition of the assets of Innocoll Inc (“Innocoll”). These assets include worldwide rights to the antibiotic surgical implant Collatamp® G for all markets except the USA, and similar rights to the late-stage development products Collatamp® G topical and implantable CollaRx® bupivacaine for post-surgery pain control. The acquisition also grants EUSA an option to the US rights for CollaRx bupivacaine. In addition, Innocoll will transfer to EUSA its pan-European sales and marketing infrastructure, which has a presence in over 20 European territories, as well as its distribution network covering more than 25 further countries around the world. As part of the agreement, Innocoll will continue to manufacture and supply the products to EUSA, and will progress the development of the late-stage clinical programmes. In return, EUSA will make an upfront payment, pay development, regulatory and sales performance milestone fees and take an equity investment in Innocoll’s parent company.

Download PDF
of transcript (76KB)